Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials

Michael S. Simberkoff, Pamela M. Hartigan, John D. Hamilton, Daniel Deykin, Mitchell Gail, John Bartlett, Paul Feorino, Robert Redfield, Richard Roberts, Dorothea Collins, David DeMets, Willis Pritchett, Norton Spritz, Richard P. Wenzel

Research output: Contribution to journalArticle

Abstract

Ethical dilemmas caused by external events and an interim subset analysis raised concerns about continuing a long-term VA clinical trial comparing early with later zidovudine therapy for symptomatic human immunodeficiency virus (HIV) infection. The first external event was the early termination of other, apparently similar, trials conducted by the AIDS Clinical Trials Group (ACTG) and the announced clear benefits for the zidovudine-treated patients. Interim analysis of the VA trial at this time did not show similar benefits. Subset analyses were performed to explore factors that might explain the different results. These suggested a difference in response to zidovudine in white and minority groups. The Data Monitoring Board and a special advisory panel reviewed these data and concluded that, since the VA results were neutral overall and the subset analyses based on small numbers, the trial should continue. By conference call, the study cochairmen and biostatistician discussed this decision with study personnel without revealing interim results, and study personnel passed the information on to patients at the participating centers. The second event was in March 1990, when the Food and Drug Administration (FDA) approved earlier use of zidovudine, which applied to patients still in the VA trial. Patients were asked to reaffirm their participation by signing a new informed consent that explained the findings reported by the ACTG, the FDA-approved revised recommendations, and the rationale for continuation of the VA trial. The consent form emphasized that continued masked therapy was optional and that unmasked treatment and follow-up would be provided to patients requesting it. Seventy-four percent of the participants chose to continue masked therapy. We conclude that when new external data are announced, informed participation in a long-term clinical trial may require revised consent form and that it is ethical and practical to present this without disclosure of interim study results.

Original languageEnglish (US)
Pages (from-to)6-18
Number of pages13
JournalControlled Clinical Trials
Volume14
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Zidovudine
Clinical Trials
Consent Forms
United States Food and Drug Administration
Acquired Immunodeficiency Syndrome
Minority Groups
Disclosure
Virus Diseases
Therapeutics
Informed Consent
HIV

Keywords

  • clinical trials
  • early stopping
  • Ethics
  • HIV infection
  • informed consent
  • zidovudine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Simberkoff, M. S., Hartigan, P. M., Hamilton, J. D., Deykin, D., Gail, M., Bartlett, J., ... Wenzel, R. P. (1993). Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. Controlled Clinical Trials, 14(1), 6-18. https://doi.org/10.1016/0197-2456(93)90046-G

Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. / Simberkoff, Michael S.; Hartigan, Pamela M.; Hamilton, John D.; Deykin, Daniel; Gail, Mitchell; Bartlett, John; Feorino, Paul; Redfield, Robert; Roberts, Richard; Collins, Dorothea; DeMets, David; Pritchett, Willis; Spritz, Norton; Wenzel, Richard P.

In: Controlled Clinical Trials, Vol. 14, No. 1, 1993, p. 6-18.

Research output: Contribution to journalArticle

Simberkoff, MS, Hartigan, PM, Hamilton, JD, Deykin, D, Gail, M, Bartlett, J, Feorino, P, Redfield, R, Roberts, R, Collins, D, DeMets, D, Pritchett, W, Spritz, N & Wenzel, RP 1993, 'Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials', Controlled Clinical Trials, vol. 14, no. 1, pp. 6-18. https://doi.org/10.1016/0197-2456(93)90046-G
Simberkoff, Michael S. ; Hartigan, Pamela M. ; Hamilton, John D. ; Deykin, Daniel ; Gail, Mitchell ; Bartlett, John ; Feorino, Paul ; Redfield, Robert ; Roberts, Richard ; Collins, Dorothea ; DeMets, David ; Pritchett, Willis ; Spritz, Norton ; Wenzel, Richard P. / Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. In: Controlled Clinical Trials. 1993 ; Vol. 14, No. 1. pp. 6-18.
@article{a09e9ea26b854859901088ff9c408902,
title = "Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials",
abstract = "Ethical dilemmas caused by external events and an interim subset analysis raised concerns about continuing a long-term VA clinical trial comparing early with later zidovudine therapy for symptomatic human immunodeficiency virus (HIV) infection. The first external event was the early termination of other, apparently similar, trials conducted by the AIDS Clinical Trials Group (ACTG) and the announced clear benefits for the zidovudine-treated patients. Interim analysis of the VA trial at this time did not show similar benefits. Subset analyses were performed to explore factors that might explain the different results. These suggested a difference in response to zidovudine in white and minority groups. The Data Monitoring Board and a special advisory panel reviewed these data and concluded that, since the VA results were neutral overall and the subset analyses based on small numbers, the trial should continue. By conference call, the study cochairmen and biostatistician discussed this decision with study personnel without revealing interim results, and study personnel passed the information on to patients at the participating centers. The second event was in March 1990, when the Food and Drug Administration (FDA) approved earlier use of zidovudine, which applied to patients still in the VA trial. Patients were asked to reaffirm their participation by signing a new informed consent that explained the findings reported by the ACTG, the FDA-approved revised recommendations, and the rationale for continuation of the VA trial. The consent form emphasized that continued masked therapy was optional and that unmasked treatment and follow-up would be provided to patients requesting it. Seventy-four percent of the participants chose to continue masked therapy. We conclude that when new external data are announced, informed participation in a long-term clinical trial may require revised consent form and that it is ethical and practical to present this without disclosure of interim study results.",
keywords = "clinical trials, early stopping, Ethics, HIV infection, informed consent, zidovudine",
author = "Simberkoff, {Michael S.} and Hartigan, {Pamela M.} and Hamilton, {John D.} and Daniel Deykin and Mitchell Gail and John Bartlett and Paul Feorino and Robert Redfield and Richard Roberts and Dorothea Collins and David DeMets and Willis Pritchett and Norton Spritz and Wenzel, {Richard P.}",
year = "1993",
doi = "10.1016/0197-2456(93)90046-G",
language = "English (US)",
volume = "14",
pages = "6--18",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials

AU - Simberkoff, Michael S.

AU - Hartigan, Pamela M.

AU - Hamilton, John D.

AU - Deykin, Daniel

AU - Gail, Mitchell

AU - Bartlett, John

AU - Feorino, Paul

AU - Redfield, Robert

AU - Roberts, Richard

AU - Collins, Dorothea

AU - DeMets, David

AU - Pritchett, Willis

AU - Spritz, Norton

AU - Wenzel, Richard P.

PY - 1993

Y1 - 1993

N2 - Ethical dilemmas caused by external events and an interim subset analysis raised concerns about continuing a long-term VA clinical trial comparing early with later zidovudine therapy for symptomatic human immunodeficiency virus (HIV) infection. The first external event was the early termination of other, apparently similar, trials conducted by the AIDS Clinical Trials Group (ACTG) and the announced clear benefits for the zidovudine-treated patients. Interim analysis of the VA trial at this time did not show similar benefits. Subset analyses were performed to explore factors that might explain the different results. These suggested a difference in response to zidovudine in white and minority groups. The Data Monitoring Board and a special advisory panel reviewed these data and concluded that, since the VA results were neutral overall and the subset analyses based on small numbers, the trial should continue. By conference call, the study cochairmen and biostatistician discussed this decision with study personnel without revealing interim results, and study personnel passed the information on to patients at the participating centers. The second event was in March 1990, when the Food and Drug Administration (FDA) approved earlier use of zidovudine, which applied to patients still in the VA trial. Patients were asked to reaffirm their participation by signing a new informed consent that explained the findings reported by the ACTG, the FDA-approved revised recommendations, and the rationale for continuation of the VA trial. The consent form emphasized that continued masked therapy was optional and that unmasked treatment and follow-up would be provided to patients requesting it. Seventy-four percent of the participants chose to continue masked therapy. We conclude that when new external data are announced, informed participation in a long-term clinical trial may require revised consent form and that it is ethical and practical to present this without disclosure of interim study results.

AB - Ethical dilemmas caused by external events and an interim subset analysis raised concerns about continuing a long-term VA clinical trial comparing early with later zidovudine therapy for symptomatic human immunodeficiency virus (HIV) infection. The first external event was the early termination of other, apparently similar, trials conducted by the AIDS Clinical Trials Group (ACTG) and the announced clear benefits for the zidovudine-treated patients. Interim analysis of the VA trial at this time did not show similar benefits. Subset analyses were performed to explore factors that might explain the different results. These suggested a difference in response to zidovudine in white and minority groups. The Data Monitoring Board and a special advisory panel reviewed these data and concluded that, since the VA results were neutral overall and the subset analyses based on small numbers, the trial should continue. By conference call, the study cochairmen and biostatistician discussed this decision with study personnel without revealing interim results, and study personnel passed the information on to patients at the participating centers. The second event was in March 1990, when the Food and Drug Administration (FDA) approved earlier use of zidovudine, which applied to patients still in the VA trial. Patients were asked to reaffirm their participation by signing a new informed consent that explained the findings reported by the ACTG, the FDA-approved revised recommendations, and the rationale for continuation of the VA trial. The consent form emphasized that continued masked therapy was optional and that unmasked treatment and follow-up would be provided to patients requesting it. Seventy-four percent of the participants chose to continue masked therapy. We conclude that when new external data are announced, informed participation in a long-term clinical trial may require revised consent form and that it is ethical and practical to present this without disclosure of interim study results.

KW - clinical trials

KW - early stopping

KW - Ethics

KW - HIV infection

KW - informed consent

KW - zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0027405578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027405578&partnerID=8YFLogxK

U2 - 10.1016/0197-2456(93)90046-G

DO - 10.1016/0197-2456(93)90046-G

M3 - Article

VL - 14

SP - 6

EP - 18

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 1

ER -